MCID: SYS038
MIFTS: 27

Systemic Lupus Erythematosus 2

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 2

MalaCards integrated aliases for Systemic Lupus Erythematosus 2:

Name: Systemic Lupus Erythematosus 2 54 71
Systemic Lupus Erythematosus, Susceptibility to, 2 13 69
Sleb2 71

Classifications:



External Ids:

OMIM 54 605218
MedGen 40 C1854577
MeSH 42 D008180

Summaries for Systemic Lupus Erythematosus 2

UniProtKB/Swiss-Prot : 71 Systemic lupus erythematosus 2: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

MalaCards based summary : Systemic Lupus Erythematosus 2, also known as systemic lupus erythematosus, susceptibility to, 2, is related to systemic lupus erythematosus and lupus erythematosus. An important gene associated with Systemic Lupus Erythematosus 2 is PDCD1 (Programmed Cell Death 1). The drugs Cyclophosphamide and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and kidney.

Description from OMIM: 605218

Related Diseases for Systemic Lupus Erythematosus 2

Symptoms & Phenotypes for Systemic Lupus Erythematosus 2

Clinical features from OMIM:

605218

Drugs & Therapeutics for Systemic Lupus Erythematosus 2

Drugs for Systemic Lupus Erythematosus 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 270)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
2
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
5
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
6
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
7
Simvastatin Approved Phase 4,Phase 1 79902-63-9 54454
8
Metformin Approved Phase 4 657-24-9 14219 4091
9
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 134070 5280453
10
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1 50-14-6 5280793
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 1406-16-2
12 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
13 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
16 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
19 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Autoantibodies Phase 4,Phase 2,Phase 3,Phase 1
24 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Micronutrients Phase 4,Phase 2,Phase 1
27 Trace Elements Phase 4,Phase 2,Phase 1
28 Vasoconstrictor Agents Phase 4,Phase 2
29 Vitamins Phase 4,Phase 2,Phase 1
30 Adrenocorticotropic Hormone Phase 4
31 beta-endorphin Phase 4
32 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
33 Hormones Phase 4,Phase 2,Phase 3,Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
35 Melanocyte-Stimulating Hormones Phase 4
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
37 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
39 Estrogens Phase 4,Phase 2
40 Estrogens, Conjugated (USP) Phase 4
41 Analgesics Phase 4,Phase 2,Phase 3
42 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
45 Antipyretics Phase 4,Phase 2,Phase 3
46 Cyclooxygenase Inhibitors Phase 4
47 Fibrinolytic Agents Phase 4,Phase 1,Phase 2
48 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Platelet Aggregation Inhibitors Phase 4,Phase 1,Phase 2
50 Rosuvastatin Calcium Phase 4,Phase 2,Phase 1 147098-20-2

Interventional clinical trials:

(show top 50) (show all 300)

id Name Status NCT ID Phase Drugs
1 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
2 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
3 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
4 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
5 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
6 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
7 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
8 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
9 The Effect of Metformin on Reducing Lupus Flares Recruiting NCT02741960 Phase 4 metformin;placebo
10 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
11 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
12 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
13 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
14 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
15 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
16 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
17 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
18 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
19 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Completed NCT01261793 Phase 3 Placebo;Epratuzumab;Epratuzumab
20 Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus Completed NCT00611663 Phase 2, Phase 3
21 Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Completed NCT00624338 Phase 2, Phase 3 Atacicept 75 mg;Atacicept 150 mg
22 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
23 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
24 On Open-Label Study in Participants With Systemic Lupus Erythematosus Completed NCT01488708 Phase 3 LY2127399;Placebo
25 A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) Completed NCT00626197 Phase 3 corticosteroids;cyclophosphamide;mycophenolate mofetil;ocrelizumab;placebo
26 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 Completed NCT00712933 Phase 3 belimumab
27 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
28 Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention Completed NCT00189124 Phase 2, Phase 3 Dehydroepiandrosterone (DHEA)
29 Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus Completed NCT00004795 Phase 2, Phase 3 dehydroepiandrosterone
30 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Completed NCT00137969 Phase 2, Phase 3 Rituximab;Placebo;Prednisone;Acetaminophen;Diphenhydramine
31 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01484496 Phase 3 Standard therapy
32 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed NCT01408576 Phase 3 Epratuzumab;Epratuzumab
33 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus Completed NCT01262365 Phase 3 Epratuzumab;Epratuzumab;Placebo
34 Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Completed NCT00065806 Phase 3 Atorvastatin;Placebo atorvastatin
35 High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide Completed NCT00005778 Phase 3 High-dose immunoablative therapy
36 Preventive IVIG Therapy for Congenital Heart Block Completed NCT00460928 Phase 2, Phase 3 intravenous immune globulin (IVIG)
37 Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus Recruiting NCT02558517 Phase 3 prednisone discontinuation
38 Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE Recruiting NCT02444728 Phase 3 Hydroxychloroquine;Cyclophosphamide;Azathioprine;Methylprednisolone
39 Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus Recruiting NCT02794285 Phase 3 Placebo
40 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia Active, not recruiting NCT01345253 Phase 3 Belimumab;Placebo
41 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Active, not recruiting NCT02504645 Phase 3 IPP-201101;Placebo
42 Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis Suspended NCT01773616 Phase 3 Oral prednisolone;Rituximab;Mycophenolate mofetil;Methyl prednisolone
43 A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) Terminated NCT00539838 Phase 3 Prednisone;immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate);methylprednisolone;ocrelizumab;placebo
44 TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Terminated NCT00368264 Phase 2, Phase 3 infliximab;placebo
45 Study of LJP 394 in Lupus Patients With History of Renal Disease Terminated NCT00089804 Phase 3 abetimus sodium (LJP 394) and/or placebo solution;abetimus sodium (LJP 394);Phosphate-buffered saline
46 Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) Terminated NCT00383214 Phase 3 Epratuzumab
47 Myfortic Versus Azathioprine in Systemic Lupus Erythematosus Terminated NCT00504244 Phase 3 switch to Myfortic;continuation of azathioprine
48 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis Terminated NCT00430677 Phase 2, Phase 3 Corticosteroids (prednisone or prednisolone);Abatacept;Abatacept;Mycophenolate mofetil (MMF);Abatacept
49 A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus Terminated NCT01240694 Phase 3 Lupuzor
50 CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Withdrawn NCT02074020 Phase 3 Blisibimod;Placebo

Search NIH Clinical Center for Systemic Lupus Erythematosus 2

Genetic Tests for Systemic Lupus Erythematosus 2

Anatomical Context for Systemic Lupus Erythematosus 2

MalaCards organs/tissues related to Systemic Lupus Erythematosus 2:

39
Skin, Bone, Kidney, T Cells, Bone Marrow, Testes, Heart

Publications for Systemic Lupus Erythematosus 2

Articles related to Systemic Lupus Erythematosus 2:

id Title Authors Year
1
Non-Hodgkin's lymphoma in patients with systemic lupus erythematosus: 2 case reports. ( 11975105 )
2002
2
Studies of peritoneal macrophage function in murine systemic lupus erythematosus. 2. Nature of elevated resident peritoneal cells in NZB and (NZB x NZW)F1 mice. ( 3861745 )
1985
3
The deoxyribonucleic acid (DNA) skin test in systemic lupus erythematosus. 2. Histological findings. ( 127605 )
1975

Variations for Systemic Lupus Erythematosus 2

Expression for Systemic Lupus Erythematosus 2

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 2.

Pathways for Systemic Lupus Erythematosus 2

GO Terms for Systemic Lupus Erythematosus 2

Sources for Systemic Lupus Erythematosus 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....